Applied Genetic Technologies

Applied Genetic Technologies is a clinical-stage biotechnology company developing genetic therapies for patients with rare and debilitating ophthalmic, otologic, and central nervous system (CNS) diseases. AGTC is designing and constructing critical gene therapy elements and integrating them to develop customized therapies that address unmet patient needs. AGTC’s most advanced clinical programs, XLRP and ACHM CNGB3, leverage its technology platform and have the potential to improve vision in patients with inherited retinal diseases. Its preclinical programs build on AGTC's AAV manufacturing technology and scientific expertise. AGTC is advancing multiple candidate programs to address significant unmet clinical needs in optogenetics, otology, and CNS disorders. The company has also established strategic collaborations with Bionic Sight, Inc. (an innovator in the emerging fields of optogenetics and retinal coding) and Otonomy, Inc. (a biopharmaceutical company focused on developing innovative neurology therapies).